Karolinska Development Portfolio Company Completes Successful Phase II Clinical TrialSTOCKHOLM - Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development’s business strategy. A Fifth of People With MDS (Blood Cancer) Die Prematurely Because the NHS Won’t Fund New Life-extending DrugsLONDON - - More Than Half of Blood Cancer Experts (56 Percent) say Less Priority is Given to Rarer Cancers Compared to Other Common Cancers Algeta Signs $800 Million (EUR560m) Global Agreement With Bayer for Development and Commercialization of Alpharadin for Bone MetastasesOSLO - - Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development Nucletron Increases Full Year Outlook After Strong First Half 2009VEENENDAAL, the Netherlands - - Despite Challenging Global Economic Conditions, Nucletron Surpassed Projections for the First Half Year Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17PHILADELPHIA - - INTUNIV, the First Nonscheduled alpha-2A receptor agonist indicated for ADHD, Demonstrated Improvement in a Range of ADHD Symptoms That can be Disruptive, Such as Inattention, Arguing With Adults, Hyperactivity, Impulsivity, and Losing One’s Temper CryoLife’s Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the WorldATLANTA - - The Ross Summit 2009 to focus on new patient data supporting the Ross heart reconstruction procedure and the use of SynerGraft(R) processed human heart valves in the Ross Procedure Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare ConferenceAURORA, Ontario - Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced that John Docherty, president and chief operating officer, will present at the Rodman and Renshaw 11th Annual Healthcare Conference at 12:05 p.m. EDT on Wednesday, Sept. 9, at the New York Palace Hotel in New York. Mr. Docherty will provide an overview of the Company’s leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company’s website, www.helixbiopharma.com, on September 9th, 2009. Health Workers Face Postcode Lottery for Swine Flu Vaccine, Chemist+Druggist RevealsTONBRIDGE, England - Thousands of frontline health workers in England are trapped in a postcode lottery after Department of Health (DH) guidance on swine flu vaccination has left local health chiefs confused over who is eligible for the jab. Rheumatoid Arthritis (RA) Patients Taking Enbrel Keep Working for LongerMAIDENHEAD, England - - Study Published in Rheumatology Underscores the Need for Early and Aggressive Treatment to Maintain Work Productivity Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotratm In RABASEL and REINACH, Switzerland - - CAPRA-2-Data Will be Used to File for US Marketing Approval Pitavastatin Demonstrates no Significant Drug-to-Drug Interaction When Administered With CYP3A4 InhibitorsBARCELONA, Spain - - Data Shows Potential Tolerability Advantage for Pitavastatin Compared With Other Statins BMI Healthcare Hospitals Offer Free Blood Pressure Checks and Advice During Know Your Numbers! Week (7-13 September)LONDON - - With Photo - One in Three People Have High Blood Pressure; Over Five Million Don’t Know it MarketsandMarkets: Global Anti Counterfeit Market for Food and Pharmaceuticals Worth US$79.3 Billion by 2014WILMINGTON, Delaware - According to a new market research report, ‘Global Anti Counterfeit market for Food and Pharmaceuticals (2009-2014)’, published by MarketsandMarkets (www.marketsandmarkets.com), the global anti counterfeit market for food and pharmaceuticals market is expected to be worth US$79.3 billion by 2014, with an estimated CAGR of 8.6% from 2009 to 2014. The North American market is expected to account for nearly 62% of the total revenues. MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014WILMINGTON, Delaware - According to a new market research report, ‘Global biosimilars Market (2009 - 2014)’, published by MarketsandMarkets (www.marketsandmarkets.com), the global biosimilars market is expected to be worth US$19.4 billion by 2014, recording a CAGR of 89.1% from 2009 to 2014. The increasing demand from patients, insurers, and government agencies to reduce the costs of blockbuster biopharmaceuticals has created numerous opportunities in the global biosimilars market. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 2014WILMINGTON, Delaware - According to a new healthcare market research report ‘Global Top Minimally Invasive/Non Invasive Market (2009 - 2014)’, published by MarketsandMarkets (www.marketsandmarkets.com), in 2009, the global minimally invasive/ non invasive market is estimated to be approximately $16.4 billion and is expected to reach $24.4 billion by 2014 at a CAGR of 8.3%. Accumetrics, Inc. Forms Partnership With Grifols as Its Distributor in Spain, Portugal and ChileSAN DIEGO - Accumetrics, Inc. has announced the signing of a new exclusive distribution agreement for its VerifyNow(R) System in Spain, Portugal and Chile with Grifols S.A.. This distribution agreement will continue to expand Accumetrics’ reach in both scope and geography, and add to the growing numbers of countries where physicians have access to the VerifyNow System. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III TrialsCAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today reported that it has completed its submission of a New Drug Application (NDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, with the U.S. Food and Drug Administration (FDA). The Company also announced positive results from the final two Phase III studies of velaglucerase alfa, with both studies reaching all of their primary and secondary endpoints. Aircraft Reports Material Expansion and Staff IncreaseEDINBURGH, Scotland - Aircraft Medical (Aircraft), the UK medical devices company, announces that it has added 25 new staff to its R&D, business development and sales teams since January 2009. MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure ProgressionNATICK, Massachusetts and BARCELONA, Spain - - Results of Landmark Heart Failure Trial Published by New England Journal of Medicine and Presented at ESC SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical CompanyAMSTERDAM - SynCo Bio Partners B.V., the expert in long term GMP contract manufacturing of biopharmaceuticals announced today that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company. Global Biomaterials Market Worth US$58.1 Billion by 2014WILMINGTON, Delaware - According to a new market research report, ‘Global biomaterials Market (2009-2014)’, published by MarketsandMarkets (www.marketsandmarkets.com), the total global biomaterials market is expected to be worth US$58.1 billion by 2014, growing at a CAGR of 15.0% from 2009 to 2014. The U.S. market is expected to account for nearly 42% of the total revenues. The biomaterials market today has already crossed $28 billion. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014WILMINGTON, Delaware - According to a new market research report, ‘Global Autoimmune Treatment Market (2009-2014)’, published by MarketsandMarkets ( www.marketsandmarkets.com), the global autoimmune treatment market is expected to be worth US$68.81 billion by 2014, with an estimated CAGR of 12.7% from 2009 to 2014. The North American market is expected to account for nearly 42% of the total revenues. Cell Biosciences Launches Unique Protein Phosphorylation Assay ServiceSANTA CLARA, California - Cell Biosciences, Inc. today launched a service program to provide phosphoprotein analysis of pre-clinical samples for pharmaceutical and biotechnology companies. Under the Cell Biosciences Focus Assay Service program, client companies receive detailed analytical information about cell signaling proteins in their specimens. This information provides insight into disease processes and aids in the development of new treatments. The service will be performed using the Cell Biosciences CB1000 system, which enables quick and quantitative analysis of critical control proteins in extremely small samples - as few as 25 cells per measurement. MarketsandMarkets: Global Biomarker Market Worth US$ 20.5 Billion by 2014WILMINGTON, Delaware - The Global Biomarker Market report analyzes the biomarker tools and services market over the period 2009-2014. The report studies the major market drivers, restraints, and opportunities for the global biomarker market; and also evaluates the major trends in the macro- and micro-markets with respect to different geographic regions. World’s Largest Medical Tourism and Global Healthcare Conference, October 26-28th, Announces Record Attendance, Distinguished Speakers and SponsorsLOS ANGELES - The 2nd Annual World Medical Tourism & Global Health Congress, the largest medical tourism congress in the world, announces speakers, sponsors and record increase in attendance this coming October 26-28th 2009 in Los Angeles, California. www.medicaltourismcongress.com/ Over 60 countries confirmed participation. Up to 5,000 private one-on-one networking sessions will be arranged through special networking software, allowing each delegate to schedule up to 80 meetings during the 3-day conference. Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & DevelopmentCOPENHAGEN and OSLO - - Experienced Biopharmaceutical Executives Form new Leadership Team at Antibody Medicines Company Pitavastatin is Non-Inferior to Atorvastatin and Simvastatin and Demonstrates Sustained Efficacy and Tolerability Over 52 WeeksBARCELONA, Spain - - Pitavastatin Represents Long-Term Treatment Option for Patients With Primary Hypercholesterolaemia or Combined Dyslipidaemia New Insights Link Low HDL-Cholesterol and Elevated Triglycerides With Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-CholesterolBARCELONA - - Surveys Establish Residual Vascular Risk is Associated With Atherogenic Dyslipidemia Suggesting the Need to Reconsider Approach to Management of Lipids Edoxaban - Next Generation Oral Anticoagulant Under Investigation to Help Prevent Stroke in Patients With Atrial FibrillationBARCELONA, Spain - - New Treatment Could Offer Further Option in Addition to Current Standard of Care in Thromboembolic Disease EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 AuctionWELLESLEY HILLS, Massachusetts - Joseph F. Finn, Jr., C.P.A. (”Finn”), announced today that the P2Y2 Gastrointestinal Early Development Candidate Program will be part of the intellectual property offered for sale at the September 30, 2009 auction. Blood Test May Predict Course of MSLONDON - Scientists have discovered a blood test that could predict the course of multiple sclerosis (MS), or even indicate who is likely to develop the condition after a first MS-like attack. Prescient Medical Inc. Featured on FOX Business NetworkDOYLESTOWN, Pennsylvania - Prescient Medical Inc. announced that CEO Patricia Scheller, appeared on FOX Business Network (FBN) to discuss the company’s groundbreaking products and recent achievement of CE Mark approval for their vProtect(TM) Luminal Shield Stent System. Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International MarketsBARCELONA, Spain - - New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes Nuevolution Announces New Research Collaboration With Big PharmaCOPENHAGEN - - Partnership to use Nuevolution’s Chemetics(R) Technology for Lead Discovery Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary SyndromesPARIS - - SEPIA-ACS Multiple-Dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet - |
